Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
暂无分享,去创建一个
Kornelia Polyak | Hailun Li | K. Polyak | R. Gelman | M. Shipitsin | S. Y. Park | H. Lee | Hailun Li | Rebecca Gelman | Michail Shipitsin | So Yeon Park | Hee Eun Lee
[1] Nicholas J. Wang,et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.
[2] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[3] M. Ringnér,et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.
[4] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[5] R. Beroukhim,et al. Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.
[6] L. Beaulieu,et al. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. , 2007, Experimental cell research.
[7] C. D. Salcido,et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.
[8] Charlotte Kuperwasser,et al. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.
[9] J. Sleeman,et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. , 2005, Cancer research.
[10] M. Clarke,et al. Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.
[11] J. Visvader,et al. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.
[12] K. Kim,et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer , 2007, Journal of Clinical Pathology.
[13] Yi Xiao,et al. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. , 2008, The American journal of pathology.
[14] W. Hahn,et al. Roots and stems: stem cells in cancer , 2006, Nature Medicine.
[15] Angel Porgador,et al. Cell type-specific DNA methylation patterns in the human breast , 2008, Proceedings of the National Academy of Sciences.
[16] D. Melton,et al. "Stemness": Transcriptional Profiling of Embryonic and Adult Stem Cells , 2002, Science.
[17] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] Elaine Fuchs,et al. Self-Renewal, Multipotency, and the Existence of Two Cell Populations within an Epithelial Stem Cell Niche , 2004, Cell.
[19] M. Wicha,et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.
[20] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[21] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[22] Marco Marra,et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. , 2008, Cell stem cell.
[23] J. Herman,et al. Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.
[24] D. Birnbaum,et al. Cancer Stem Cells in Breast: Current Opinion and Future Challenges , 2008, Pathobiology.
[25] F. Bertucci,et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.
[26] I. Giannopoulou,et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. , 2008, Human pathology.
[27] Kornelia Polyak,et al. Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.
[28] Jean Paul Thiery,et al. Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.
[29] Daniel Birnbaum,et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.
[30] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Sørlie,et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.
[32] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[33] Jeffrey M. Rosen,et al. The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.
[34] G. Heppner,et al. Tumor heterogeneity: biological implications and therapeutic consequences , 2004, Cancer and Metastasis Reviews.
[35] S. Morrison,et al. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.
[36] Harikrishna Nakshatri,et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.
[37] Zena Werb,et al. GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.
[38] C. Pilarsky,et al. CD24 expression is a new prognostic marker in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] John T. Dimos,et al. A Stem Cell Molecular Signature , 2002, Science.
[40] Marie-Liesse Asselin-Labat,et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.
[41] Charles M. Perou,et al. Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.
[42] Gema Moreno-Bueno,et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.
[43] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[44] S. Y. Park,et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. , 2002, Human pathology.
[45] S. Fox,et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.
[46] Maria Athelogou,et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] Kornelia Polyak,et al. Breast cancer: origins and evolution. , 2007, The Journal of clinical investigation.
[48] E. Thompson,et al. Mesenchymal to Epithelial Transition in Development and Disease , 2007, Cells Tissues Organs.